Partner Headlines - AMGN

  1. Chardan Upgrades Regeneron Amid Relative Underperformance To ...

    Benzinga
  2. Gilead, Johnson & Johnson or Roche?

    GuruFocus
  3. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga
  4. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement ...

    Benzinga
  5. The Generic Drug Battle

    Benzinga
  6. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD
  7. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, ...

    Benzinga
  8. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga
  9. Leerink Is Back On Board The Biotech Train

    Benzinga
  10. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD
  11. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus
  12. Maybe Some Good News For A Big Biotech ETF

    Benzinga
  13. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga
  14. Earnings Recap For January 28

    Benzinga
  15. FDA Accepts Amgen's Biosimilar Biologics License Application ...

    Benzinga
  16. Regeneron Is Now A Sell For Chardan

    Benzinga
  17. Big Earnings Expectations For Big Biotech

    Benzinga
  18. Amgen's Vectibix, Best Supportive Care Improves Overall Survival ...

    Benzinga
  19. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for ...

    Benzinga
  20. Medicines Company Spikes On Report Of Possible Sale

    IBD
  21. Jim Cramer Likes Amgen

    Benzinga
  22. Write A Prescription For This Healthcare ETF

    Benzinga
  23. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD
  24. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD
  25. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga
  26. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  27. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; ...

    Benzinga
  28. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire ...

    Benzinga
  29. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers ...

    Benzinga
  30. Benzinga's Top #PreMarket Gainers

    Benzinga
  31. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus
  32. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  33. Dividend Growth Skids To Halt For S&P 500

    IBD
  34. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  35. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga
  36. Big Cap 20 Stocks Setting Up In Bases

    IBD
  37. Analyzing Amgen's Dividend Hike

    GuruFocus
  38. 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

    Benzinga
  39. Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma ...

    Benzinga
  40. EC Approves Amgen's IMLYGIC as First Oncolytic Immunotherapy ...

    Benzinga
  41. 4 Top Dividend Plays To Help Cure Stock Price Blues

    IBD
  42. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD
  43. Allergan Among Health Care Holdings in Alan Fournier's Portfolio

    GuruFocus
  44. Benzinga's Top Upgrades

    Benzinga
  45. Benzinga's Top #PreMarket Gainers

    Benzinga
  46. Amgen Shares Move Higher Following Morgan Stanley Upgrade To ...

    Benzinga
  47. Amgen Submits Application to EMA To Expand Indication Of Kyprolis ...

    Benzinga
  48. Amgen Announces New Analyses Presented At #ASH2015 Demonstrate ...

    Benzinga
  49. Amgen Announces Pivotal Head-To-Head ENDEAVOR Study Results Published ...

    Benzinga
  50. Amgen, Merck target cancer

    IBD
  51. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD
  52. LinkedIn, Palo Alto, Regeneron Profit Estimates Rising

    IBD
  53. Application for Amgen's Biosimilar Candidate to Humira, Submitted ...

    Benzinga
  54. Benzinga's M&A Chatter for Tuesday December 1, 2015

    Benzinga
  55. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  56. EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia ...

    Benzinga
  57. CVS Makes Amgen New BFF

    IBD
  58. CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi

    IBD
  59. European Commission Approves Kyprolis® (carfilzomib) For Combination ...

    Benzinga
  60. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  61. Regeneron Tests Buy Point As New Drug Shows Promise

    IBD
  62. Regeneron Recovers From Clinton Biotech Beat Down

    IBD
  63. Benzinga's M&A Chatter for Tuesday November 10, 2015

    Benzinga
  64. Amgen Issues Presentation of Results from Phase 3 Study Showing ...

    Benzinga
  65. Amgen Announces Etelcalcetide Met Primary Endpoint of Non-Inferiority ...

    Benzinga
  66. ICYMI: Berkshire Hathaway Just Reported Earnings Of $2,769 Per ...

    Benzinga
  67. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga
  68. Regeneron Q3 Beats Views, But Praluent Launch Slow

    IBD
  69. AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance

    IBD
  70. 10 Stocks To Watch For October 29, 2015

    Benzinga
  71. Buffalo Wild, GoPro Among Flurry Of Late Wed. Earnings

    IBD
  72. Amgen Crushes EPS Views

    IBD
  73. Amgen Q3 Earnings Beat; Sales Growth Best In Years

    IBD
  74. Amgen Posts Upbeat Q3 Results, Lifts Forecast

    Benzinga
  75. Lifelock, Yelp Surge Following Earnings Report; B-Dubs, GoPro ...

    Benzinga
  76. Wild Short Interest Swings For Three Top Biotech Stocks

    Benzinga
  77. Keep an Eye on These 10 Stocks for October 28, 2015

    Benzinga
  78. Stocks End Lower; Apple Up, Twitter Down After Hours

    IBD
  79. Amgen and Cytokinetics Announce Positive Top-Line Results From ...

    Benzinga
  80. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  81. 10 S&P 100 Companies Paying The Highest And Lowest Taxes

    Benzinga
  82. Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene ...

    Benzinga
  83. Cowen: In Biotech Earnings We Trust

    Benzinga
  84. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  85. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  86. Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy ...

    Benzinga
  87. Eli Lilly Pulls Cholesterol Drug

    IBD
  88. AMGEN

    IBD
  89. After-Hours Action: JetBlue, Amgen, Medtronic

    IBD
  90. New Exploratory Analysis Showed Romosozumab Increased Estimated ...

    Benzinga
  91. Regeneron Stock Pops But Hits Resistance At 50-Day

    IBD
  92. Lilly Kills 'High Risk/High Reward' Cholesterol Drug

    IBD
  93. Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives

    Benzinga
  94. Amgen Announces New Data Show Greater Bone Mineral Density Gains ...

    Benzinga
  95. Benzinga's M&A Chatter for Wednesday October 7, 2015

    Benzinga
  96. A Cholesterol Drug Revolution

    IBD
  97. Amgen's 1990 Base Breakout Launched Major Price Move

    IBD
  98. Stocks Fade After Solid Start; Tesla, Adobe Weigh On Nasdaq

    IBD
  99. Regeneron, Amgen Up As PCSK9s Gain Key Coverage

    IBD
  100. Stocks Surge In Mixed Volume; Amgen, Global Payments Rocket

    IBD
Trading Center